Call Us : (240)403-4212

What we do?


Shuttle Pharmaceuticals is developing first-in-class therapies to improve the outcomes of patients receiving radiation therapy for the treatment of cancers. The focus is on products with unique properties to sensitize cancer cells, protect normal tissues and monitor clinical responses to treatment.


We have built a platform technology to advance the discovery and development of novel small molecules to modify the effects of ionizing radiations on cancer cells and normal tissues. To accomplish this goal, we have developed strategic collaborations to leverage programs that include drug discovery, preclinical studies of radiation sensitizers, protectors and epigenetic therapeutics, a phase I clinical trial of a radiation sensitizer and biomarkers for monitoring clinical responses to therapy.

Meet The Management Team

What We See